Abstract: A method of generating a calibration factor is described. In an example, the method may include establishing a wireless communication connection with a fitness machine. The method may also include obtaining first machine data from the fitness machine. The first machine data may specify a type of the fitness machine. The method may also include initiating a workout session on the wearable computer based on the first machine data. During the workout session, the method may also include obtaining sensor data, obtaining second machine data, and determining the calibration factor based on the second machine data and the sensor data. The method may also include generating a workout session summary based on the calibration factor.

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract: An aqueous tannin stain-inhibiting coating composition comprising a titanate coupling agent. Also, a process for inhibiting tannin staining in a tannin-containing substrate is disclosed which involves applying to the substrate a coating composition comprising a titanate coupling agent.

Abstract: Damage to the gastrointestinal tract as a consequence of exposure to ionising radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.